CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Pharmacogenomics Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.tpj.6500218PMID 14647405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

  2003cited by this paper
• Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

  2002cited by this paper
• Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

  2002cited by this paper
• Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

  2002cited by this paper
• Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

  2002cited by this paper
• CYP3A5 variant allele frequencies in Dutch Caucasians.

  2002cited by this paper
• Identification of the novel splicing variants for the hPXR in human livers.

  2002cited by this paper
• Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.

  2002cited by this paper
• The genetic determinants of the CYP3A5 polymorphism.

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.

  2001cited by this paper
• Genetic polymorphism of cytochrome P450 3A5 in Chinese.

  2001cited by this paper
• Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

  2000cited by this paper
• Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

  1999cited by this paper
• Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4

  1999cited by this paper
• Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine.

  1998cited by this paper
• Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects

  1998cited by this paper
• Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase.

  1997cited by this paper
• Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes

  1996cited by this paper
• Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes.

  1996cited by this paper
• Midazolam is metabolized by at least three different cytochrome P450 enzymes.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• The role of individual human cytochromes P450 in drug metabolism and clinical response.

  1992cited by this paper
• Nonlinear first-pass metabolism of nifedipine in healthy subjects.

  1991cited by this paper
• Interaction of citrus juices with felodipine and nifedipine.

  1991cited by this paper
• Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

  1990cited by this paper
• Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.

  1989cited by this paper
• The pharmacokinetics of oral nifedipine--a population study.

  1988cited by this paper
• The first pass metabolism of nifedipine in man.

  1984cited by this paper

• Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans

  2018cites this paper
• Genetic variation of CYP3A5 influences paclitaxel/carboplatin‐induced toxicity in Chinese epithelial ovarian cancer patients

  2016cites this paper
• CYP3A5 Polymorphism In Serbian Paediatric Epileptic Patients On Carbamazepine Treatment

  2015cites this paper
• Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)

  2014cites this paper
• Relative Contributions of Cytochrome CYP 3 A 4 Versus CYP 3 A 5 for CYP 3 A-Cleared Drugs Assessed In Vitro Using a CYP 3 A 4-Selective Inactivator ( CYP 3 cide ) s

  2014cites this paper
• DMD057000 1163..1173

  2014cites this paper
• Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?

  2013cites this paper
• Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs

  2012cites this paper
• A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic

  2012cites this paper
• A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics

  2012cites this paper
• Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic

  2012cites this paper
• Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients

  2011cites this paper
• Inferences from targeting CYP450 modulation to decrease the risk of induced cataract in the experimental model?

  2011cites this paper
• Pharmacogenetics and Pharmacogenomics

  2010cites this paper
• Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers

  2010cites this paper
• Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations

  2010cites this paper
• Influence of CYP3A5 and MDR1 Genetic Polymorphisms on Urinary 6β‐Hydroxycortisol/Cortisol Ratio After Grapefruit Juice Intake in Healthy Chinese

  2010cites this paper
• Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition

  2010cites this paper
• The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

  2009cites this paper
• CYP3A4 and CYP3A5 Polymorphisms and Blood Pressure Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal Disease

  2009cites this paper
• Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady‐state in Korean epileptic patients

  2009cites this paper
• CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

  2009cites this paper
• Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort

  2009cites this paper
• Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

  2009cites this paper
• Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin

  2008cites this paper
• Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

  2008cites this paper
• Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs

  2008cites this paper
• Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects

  2008cites this paper
• Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.

  2008cites this paper
• Factors Affecting Pharmacokinetic Variability of Imatinib Mesylate (Gleevec, STI-571)

  2008cites this paper
• Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy

  2008cites this paper
• Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

  2007cites this paper
• Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam

  2007cites this paper
• So Many Studies, Too Few Subjects: Establishing Functional Relevance of Genetic Polymorphisms on Pharmacokinetics

  2006cites this paper
• Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects

  2006cites this paper
• CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

  2006cites this paper
• Clinical implications of CYP3A polymorphisms

  2006cites this paper
• Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated With CYP3A5*3 Allele or a Change in Diet Composition

  2006cites this paper
• Significance of the Minor Cytochrome P450 3A Isoforms

  2006cites this paper
• Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.

  2006cites this paper
• Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

  2005cites this paper
• CYP 3 A 5 mRNA Degradation by Nonsense-Mediated mRNA Decay

  2005cites this paper
• Genotype‐phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance in Vivo

  2005cites this paper
• CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay

  2005cites this paper
• Qualitative and Quantitative Assessment of Cytochromes P450 mRNA in Human : Studies in the Liver, Blood and Gastrointestinal Mucosa

  2005cites this paper
• Association of CYP 2 C 8 , CYP 3 A 4 , CYP 3 A 5 , and ABCB 1 Polymorphismswith thePharmacokinetics of Paclitaxel

  2005cites this paper
• Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5

  2005cites this paper
• Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

  2005cites this paper
• Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

  2004cites this paper
• Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions

  2004cites this paper
• Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms

  2004cites this paper
• Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

  2004cites this paper
• Genetic variability in CYP3A5 and its possible consequences.

  2004cites this paper